【24h】

Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia.

机译:在菌血肺炎骨膜肺炎中加入Macroolide至SS-incaM。

获取原文
获取原文并翻译 | 示例
       

摘要

In the study presented here, data collected prospectively from 340 adult patients hospitalised in five countries with bacteremic pneumococcal CAP and treated with a ss-lactam +/- a macrolide were analysed retrospectively to evaluate the efficacy of this antimicrobial combination. Univariate and multivariate analyses revealed no significant effect on case fatality rate when a macrolide/ss-lactam regimen was used as initial therapy. Results were not affected by severity of illness, or by excluding patients who died within 2 days of admission. Identified predictors of death in a multivariate regression model were age >65 years (OR=2.6), two or more lung lobes affected (OR=2.2), and severity of disease as estimated using the acute physiology score (APS)>8.
机译:在此处提出的研究中,重新分析了在五个患有菌血肺纤维帽的340名成年患者中预期收集的数据,并用SS-lactam +/-大环内酯进行治疗,评估该抗菌组合的功效。 单变量和多变量分析显示,当Macroolide / SS-Lactam方案用作初始治疗时,对病例死亡率没有显着影响。 结果不受疾病严重程度的影响,或者通过排除在入场后2天内死亡的患者。 确定多元回归模型的死亡预测因子是年龄> 65岁(或= 2.6),受影响(或= 2.2)的两种或更多种肺裂隙,以及使用急性生理评分(APS)> 8估计的疾病严重程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号